What is Catalyst Pharmaceuticals Inc?
, a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 3.85B, and a P/E ratio of 18.2x.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.